• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

How I treat older patients with acute myeloid leukemia.

作者信息

Arellano Martha, Carlisle Jennifer Wilkinson

机构信息

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

Hematology and Medical Oncology Fellowship Training Program, Emory University, Atlanta, Georgia.

出版信息

Cancer. 2018 Jun 15;124(12):2472-2483. doi: 10.1002/cncr.31347. Epub 2018 May 29.

DOI:10.1002/cncr.31347
PMID:29809277
Abstract
摘要

相似文献

1
How I treat older patients with acute myeloid leukemia.我如何治疗老年急性髓系白血病患者。
Cancer. 2018 Jun 15;124(12):2472-2483. doi: 10.1002/cncr.31347. Epub 2018 May 29.
2
FLAI induction regimen in elderly patients with acute myeloid leukemia.老年急性髓系白血病患者的FLAI诱导方案
Leuk Lymphoma. 2019 Dec;60(13):3339-3340. doi: 10.1080/10428194.2019.1620943. Epub 2019 Jun 4.
3
Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.地西他滨与强化化疗治疗新诊断的老年急性髓系白血病患者的比较
Clin Lymphoma Myeloma Leuk. 2019 May;19(5):290-299.e3. doi: 10.1016/j.clml.2019.02.002. Epub 2019 Feb 20.
4
Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.地西他滨、伊达比星、阿糖胞苷和粒细胞集落刺激因子联合（DIAG）方案治疗高危骨髓增生异常综合征和急性髓系白血病。
Ann Hematol. 2019 Sep;98(9):2223-2225. doi: 10.1007/s00277-019-03674-2. Epub 2019 Apr 12.
5
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.与传统化疗相比，在高危骨髓肿瘤中，先用地西他滨进行表观遗传启动，再给予低剂量伊达比星/阿糖胞苷，具有增强的抗白血病作用。
Leuk Lymphoma. 2016;57(6):1311-8. doi: 10.3109/10428194.2015.1091931. Epub 2015 Oct 13.
6
Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia.在全剂量伊达比星和阿糖胞苷治疗难治性/复发性急性髓系白血病之前成功使用地西他滨治疗
Acta Haematol. 2017;137(4):195-200. doi: 10.1159/000464013. Epub 2017 Apr 27.
7
Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.第 15 天骨髓驱动的年轻成人急性髓系白血病双重诱导：可行性、毒性和治疗结果。
Am J Hematol. 2010 Sep;85(9):687-90. doi: 10.1002/ajh.21791.
8
Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission.地西他滨与中剂量阿糖胞苷巩固治疗后行HLA配型不合外周血干细胞输注用于初治缓解的老年急性髓系白血病患者
Leuk Lymphoma. 2018 Jul;59(7):1652-1658. doi: 10.1080/10428194.2017.1390235. Epub 2017 Oct 18.
9
Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype.急性髓系白血病中基于大剂量阿糖胞苷的诱导治疗后进行造血干细胞移植的结果：核型的影响
Leuk Lymphoma. 2008 Dec;49(12):2284-90. doi: 10.1080/10428190802474454.
10
FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.氟达拉滨、阿糖胞苷、伊达比星和依托泊苷（FLAIE），一种用于成人急性髓性白血病的四联诱导化疗方案：单中心经验
Am J Hematol. 2009 Oct;84(10):690-2. doi: 10.1002/ajh.21516.

引用本文的文献

1
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax.接受低甲基化药物和 venetoclax 治疗的急性髓系白血病患者的预后风险特征。
Blood Adv. 2024 Feb 27;8(4):927-935. doi: 10.1182/bloodadvances.2023011757.
2
Updates on the Management of Acute Myeloid Leukemia.急性髓系白血病管理的最新进展
Cancers (Basel). 2022 Sep 29;14(19):4756. doi: 10.3390/cancers14194756.
3
What to use to treat AML: the role of emerging therapies.治疗 AML 用什么：新兴疗法的作用。
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):16-23. doi: 10.1182/hematology.2021000309.
4
Clinical and immunological features of platelet transfusion refractoriness in young patients with de novo acute myeloid leukemia.初诊急性髓系白血病患者血小板输注无效的临床和免疫学特征。
Cancer Med. 2020 Jul;9(14):4941-4948. doi: 10.1002/cam4.3140. Epub 2020 May 18.
5
HO-1 promotes resistance to an EZH2 inhibitor through the pRB-E2F pathway: correlation with the progression of myelodysplastic syndrome into acute myeloid leukemia.HO-1 通过 pRB-E2F 通路促进对 EZH2 抑制剂的耐药性：与骨髓增生异常综合征向急性髓系白血病进展的相关性。
J Transl Med. 2019 Nov 11;17(1):366. doi: 10.1186/s12967-019-2115-9.
6
Minimal/Measurable Residual Disease Monitoring in -Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.伴有突变的急性髓系白血病中的微小残留病监测：临床观点和展望。
Int J Mol Sci. 2018 Nov 6;19(11):3492. doi: 10.3390/ijms19113492.